FDA Clears Registrational TEMPO-1 Study of CRB-701
FDA cleared Corbus Pharmaceuticals to initiate TEMPO-1, a 250-patient randomized registrational study of CRB-701 in second-line oropharyngeal cancer. The nectin-4-directed antibody-drug conjugate previously produced a 42.9% response signal in a small early cohort. The…
